Drugs / MenACWY conjugate vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00196963 | Mar → Jul 2005 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00196950 | Sep → Oct 2003 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-24 | GlaxoSmithKline | Regulatory GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-24 | GlaxoSmithKline | GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY conjugate vaccine | “The purpose of this study is to evaluate the safety, reactogenicity, immunogenicity and persistence up to three years after administration of one dose of the MenACWY conjugate...” NCT00196950 ↗1“3 formulations of GSK's MenACWY conjugate vaccine will be administered in a double-blind manner” NCT00196963 ↗ |
| Modality | Vaccine | “GSK's MenACWY conjugate vaccine” NCT00196950 ↗ |
| Route | Intramuscular | “One Intramuscular Dose of GSK Biologicals' MenACWY Conjugate Vaccine” NCT00196950 ↗ |